Diabetes Mellitus — Pathology

Diabetes mellitus (DM) is a group of metabolic disorders sharing the common phenotype of chronic hyperglycaemia, resulting from defects in insulin secretion, insulin action, or both. For NEET PG, the pathology of DM is overwhelmingly a histology and morphology topic — islet changes (insulitis vs amyloid), and the chronic microvascular lesions of kidney, eye and nerve. The single highest-yield image you must recognise is the Kimmelstiel-Wilson nodule.

Classification

The aetiological (ADA / WHO) classification you must know cold:

Type	Core defect	Pancreatic islet pathology	Typical patient
Type 1 DM	Autoimmune β-cell destruction → absolute insulin deficiency	Insulitis (lymphocytic infiltrate), then islet atrophy/loss of β-cells	Child/adolescent, lean, ketosis-prone
Type 2 DM	Insulin resistance + relative insulin deficiency / β-cell dysfunction	Amyloid (IAPP/amylin) deposition, β-cell exhaustion, mild loss	Adult, obese, ketosis-resistant
MODY	Monogenic β-cell defect (HNF1A, glucokinase, etc.)	Variable, autosomal dominant	Young, non-obese, non-autoimmune
Gestational DM	Insulin resistance of pregnancy	—	Second/third trimester
Secondary	Pancreatic destruction (chronic pancreatitis, haemochromatosis, CF), drugs (steroids), endocrinopathy (Cushing, acromegaly, phaeochromocytoma)	Underlying disease pathology	Variable

High-yield: Type 1 = insulitis; Type 2 = islet amyloid (amylin / IAPP). These two histology findings are the most repeated islet-pathology questions.

Etiology & Pathophysiology

Type 1 DM

• Autoimmune destruction of β-cells, T-cell mediated (CD8 cytotoxic T cells dominate the insulitic infiltrate, with CD4 and macrophages).
• Genetics: strongest link is HLA-DR3 and DR4 (HLA-DQ on chromosome 6p21). Concordance in monozygotic twins ~30–70%.
• Autoantibodies (markers, appear before clinical disease): anti-GAD65 (glutamic acid decarboxylase), IA-2 / ICA-512, insulin autoantibodies (IAA), and ZnT8. GAD65 is the most clinically used.
• Triggers proposed: viral (coxsackie B, mumps, rubella), molecular mimicry.
• Result: absolute insulin deficiency → unopposed glucagon → lipolysis, ketogenesis → DKA risk.

Type 2 DM

• Two core defects: (1) peripheral insulin resistance (muscle, fat, liver) and (2) β-cell dysfunction/exhaustion.
• Strong polygenic and environmental basis — obesity (visceral adiposity), inactivity. Monozygotic twin concordance ~70–90% (higher than T1).
• Islet amyloid polypeptide (IAPP / amylin) is co-secreted with insulin; chronic hypersecretion → amyloid deposition between capillaries and β-cells → β-cell apoptosis. Amyloid is eosinophilic, Congo-red positive, apple-green birefringent.
• Adipokine dysregulation: ↑ free fatty acids, ↑ resistin, ↑ inflammatory cytokines (TNF-α, IL-6), ↓ adiponectin → worsened resistance.
• Ketosis is uncommon because residual insulin suppresses lipolysis — but HHS (hyperosmolar hyperglycaemic state) can occur.

Mechanisms of chronic tissue damage (the "how" of complications)

Chronic hyperglycaemia injures tissues by four interlinked pathways — remember the framework:

1. Non-enzymatic glycation → AGEs (Advanced Glycation End-products): AGEs cross-link collagen and bind RAGE receptors → ROS, NF-κB activation, basement-membrane thickening, vascular stiffening. HbA1c itself is glycated haemoglobin.
2. Polyol (sorbitol) pathway: excess glucose → aldose reductase → sorbitol (+ fructose). Sorbitol accumulates in tissues that do not need insulin for glucose uptake (nerve, lens, retina, kidney) → osmotic injury + NADPH depletion → oxidative stress. This underlies cataract and neuropathy.
3. Protein kinase C (PKC) activation: via DAG → VEGF (neovascularisation), endothelin, TGF-β → angiogenesis and matrix expansion.
4. Hexosamine pathway → ↑ PAI-1, TGF-β.

High-yield: The polyol/sorbitol pathway via aldose reductase is the most-asked mechanism for diabetic cataract and peripheral neuropathy (insulin-independent tissues: nerve, lens, kidney, retina, RBC, blood vessels).

Stepwise flow of microvascular disease: Hyperglycaemia → AGE formation + sorbitol accumulation + PKC activation → GBM and capillary basement-membrane thickening (the hallmark) → hyaline arteriolosclerosis (afferent + efferent) → ischaemia + leakiness → nephropathy, retinopathy, neuropathy.

Pancreatic Islet Morphology

Type 1

• Early/active: insulitis — lymphocytic infiltrate around and within islets. β-cell numbers reduced.
• Late: islets become small, atrophic, fibrotic; near-total loss of β-cells with relative preservation of α, δ, PP cells.

Type 2

• Amyloid replacement of islets (amylin) — pink hyaline material on H&E, Congo red positive.
• Subtle decrease in β-cell mass; islets may appear relatively normal early.

High-yield: "Pink amorphous deposits in islets of a 55-year-old obese diabetic, Congo-red positive" = amylin (IAPP) amyloid of Type 2 DM.

Diabetic Nephropathy

The leading cause of end-stage renal disease (ESRD) worldwide. The renal lesions are the most heavily tested part of DM pathology.

Lesion	Description	Notes
Diffuse mesangial sclerosis + GBM thickening	Earliest and most common universal change	Diffuse increase in mesangial matrix
Nodular glomerulosclerosis (Kimmelstiel-Wilson nodules)	Round, laminated, PAS-positive eosinophilic nodules in the mesangium at the glomerular periphery	Pathognomonic / highly specific for DM
Hyaline arteriolosclerosis	Affects both afferent AND efferent arterioles	Efferent involvement is fairly specific to DM
Armanni-Ebstein change	Glycogen accumulation (vacuolation) in proximal & distal tubular epithelium	Seen in poorly controlled DM with severe glycosuria
Papillary necrosis	Often with superimposed pyelonephritis	Diabetics prone to UTI/pyelonephritis

High-yield (most-tested fact in DM pathology): Kimmelstiel-Wilson nodules = nodular glomerulosclerosis = round, laminated, PAS-positive acellular mesangial nodules. Highly specific for diabetic nephropathy. Eponym alone is a frequent one-liner answer.

High-yield: In DM, hyaline arteriolosclerosis involves BOTH afferent and efferent arterioles — in hypertension it is mainly the afferent. Efferent hyalinosis raises intraglomerular pressure → hyperfiltration injury.

High-yield: Armanni-Ebstein lesion = glycogen vacuolation of renal tubular epithelium (PAS-positive, dissolves in routine processing leaving clear cells). A classic "tubule" answer to distinguish from glomerular changes.

Clinical-pathological progression of nephropathy:

1. Hyperfiltration / glomerular hypertrophy (↑ GFR) — earliest, functional.
2. GBM thickening + mesangial expansion — structural.
3. Microalbuminuria (30–300 mg/day) — earliest clinical marker, also a marker of generalised endothelial dysfunction/CV risk.
4. Overt proteinuria / macroalbuminuria (>300 mg/day) → nephrotic range possible.
5. Declining GFR → ESRD.

High-yield: Microalbuminuria (30–300 mg/24h, or urine albumin-creatinine ratio 30–300 mg/g) is the earliest clinical indicator of diabetic nephropathy and an independent cardiovascular risk marker.

Diabetic Retinopathy

Leading cause of blindness in working-age adults. Pathogenesis: capillary basement-membrane thickening, pericyte loss, microaneurysms.

Two stages:

1. Non-proliferative (background) retinopathy — microaneurysms (earliest visible lesion), dot-and-blot haemorrhages, hard exudates (lipid), soft exudates / cotton-wool spots (nerve-fibre-layer microinfarcts), venous beading.
2. Proliferative retinopathy — VEGF-driven neovascularisation → fragile vessels → vitreous haemorrhage, traction retinal detachment. Treatment: pan-retinal laser photocoagulation ± anti-VEGF.

• Diabetic maculopathy / macular oedema is the commonest cause of visual loss in Type 2.
• Cataract (sorbitol/osmotic, lens) and glaucoma are also increased.

High-yield: Pericyte loss → microaneurysm is the earliest histological event; microaneurysm is the earliest ophthalmoscopically visible lesion. Neovascularisation defines the proliferative stage and is VEGF-mediated.

Diabetic Neuropathy

• Distal symmetric sensorimotor polyneuropathy is the commonest pattern ("glove-and-stocking"). Sensory > motor; predisposes to neuropathic (Charcot) joints and foot ulcers.
• Autonomic neuropathy: gastroparesis, postural hypotension, erectile dysfunction, neurogenic bladder, "silent" MI.
• Mononeuropathy / mononeuritis multiplex: e.g., CN III palsy with pupil sparing (ischaemic — somatic motor fibres affected, peripheral pupillary parasympathetic fibres spared).
• Pathology: axonal degeneration + segmental demyelination, microangiopathy of vasa nervorum, plus sorbitol-mediated osmotic injury.

High-yield: Diabetic third-nerve palsy spares the pupil (vasa nervorum ischaemia of central motor fibres); a compressive (aneurysm) third-nerve palsy involves the pupil.

Macrovascular Disease & Other Complications

• Accelerated atherosclerosis → MI (commonest cause of death in DM), stroke, peripheral vascular disease, gangrene of lower limb (DM is the leading cause of non-traumatic limb amputation).
• Infections: poor neutrophil function + vascular insufficiency → mucormycosis (rhino-orbital, in DKA), malignant otitis externa (Pseudomonas), emphysematous pyelonephritis/cholecystitis, candidiasis, TB, foot infections.
• Skin: necrobiosis lipoidica diabeticorum, acanthosis nigricans (insulin resistance marker), diabetic dermopathy.
• Acute metabolic: DKA (T1) and HHS (T2).

Feature	DKA	HHS
Typical type	Type 1	Type 2 (elderly)
Glucose	usually 250–600 mg/dL	very high, often >600–1000
Ketones	strongly positive	minimal/absent
Acidosis	metabolic acidosis, ↑ anion gap	mild/none
Osmolality	raised	markedly raised (>320 mOsm/kg)
Onset	hours–1 day	days

Diagnosis & Investigation of Choice

Diagnostic criteria (ADA) — know the cut-offs precisely:

Test	Diabetes	Prediabetes
Fasting plasma glucose (FPG)	≥126 mg/dL (≥7.0 mmol/L)	100–125 (IFG)
2-h OGTT (75 g)	≥200 mg/dL (≥11.1 mmol/L)	140–199 (IGT)
HbA1c	≥6.5%	5.7–6.4%
Random glucose + symptoms	≥200 mg/dL with classic symptoms	—

• HbA1c reflects average glycaemia over ~8–12 weeks (RBC lifespan ~120 days). Falsely low in haemolysis, blood loss, pregnancy; falsely high in iron-deficiency anaemia, splenectomy. HbA1c is the investigation of choice for monitoring control.
• Fructosamine (glycated albumin) reflects ~2–3 weeks — used when HbA1c unreliable (haemoglobinopathy, pregnancy).
• C-peptide distinguishes type: low/absent in T1, normal/high in early T2 — best marker of endogenous insulin reserve.
• Urine albumin-creatinine ratio (ACR) for nephropathy screening (annually).

High-yield: HbA1c ≥6.5% is diagnostic. C-peptide differentiates Type 1 (low) from Type 2 (normal/high) — exogenous insulin contains no C-peptide, so C-peptide measures only endogenous secretion.

Management / Drug of Choice (pathology-relevant pearls)

• Type 1: insulin (lifelong) — basal-bolus.
• Type 2 first-line: metformin (biguanide) — ↓ hepatic gluconeogenesis, weight-neutral, no hypoglycaemia; avoid in eGFR <30 (lactic acidosis risk).
• Cardio-renal protection: SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 agonists (semaglutide) reduce CV events and slow nephropathy — preferred add-ons in CKD/heart failure.
• Diabetic nephropathy: ACE inhibitor / ARB is the drug of choice for albuminuria — reduce intraglomerular pressure (efferent arteriolar dilation) and slow progression.
• Proliferative retinopathy: laser photocoagulation; macular oedema: anti-VEGF.

High-yield: ACE-I / ARB are renoprotective in DM by dilating the efferent arteriole, lowering intraglomerular pressure and proteinuria.

Key Differentials

• Nodular glomerulosclerosis mimics: the big NEET PG trap. Other causes of nodular glomerular lesions →
  • Amyloidosis (Congo red +, apple-green birefringence — KW nodules are Congo red negative, PAS +).
  • Light-chain deposition disease (MIDD) — Congo red negative, kappa light chains.
  • Membranoproliferative GN.
• Insulitis differential: autoimmune (T1) vs none in T2.
• Type 1 vs Type 2 distinction — table above; use C-peptide and antibodies.
• Causes of cotton-wool spots: DM, hypertension, HIV, anaemia, collagen vascular disease.

High-yield: Kimmelstiel-Wilson nodules are PAS-positive and Congo-red NEGATIVE; amyloid nodules are Congo-red positive. This single distinction is a classic exam discriminator.

Recently asked / exam angle

• "Most specific renal histology in DM?" → Kimmelstiel-Wilson (nodular glomerulosclerosis), PAS-positive.
• "Earliest clinical marker of diabetic nephropathy?" → microalbuminuria.
• "Glycogen in renal tubular cells of a diabetic?" → Armanni-Ebstein lesion.
• "Islet histology in Type 2 DM?" → amyloid (amylin/IAPP) deposition.
• "Islet histology in Type 1 DM?" → insulitis (lymphocytic infiltrate).
• "Enzyme of polyol pathway / cause of diabetic cataract?" → aldose reductase → sorbitol.
• "DM third-nerve palsy?" → pupil-sparing.
• "Both afferent and efferent arteriolar hyalinosis?" → diabetes (HTN = afferent mainly).
• "Antibody most associated with Type 1?" → anti-GAD65; HLA-DR3/DR4.
• "Image-based:" Congo red vs PAS staining to separate amyloid from KW nodule; cotton-wool spots and microaneurysms on fundus images.

Classic mnemonic for chronic complications — "The 3 N's + macro": Nephropathy, Neuropathy, retiNopathy (microvascular) + macrovascular atherosclerosis.

Mnemonic for insulin-independent tissues (sorbitol injury) — "LENS-R": Lens, Endothelium/blood vessels, Nerves, Schwann/kidney, Retina & RBC.

Rapid revision

1. Type 1 = insulitis (CD8 T-cell islet infiltrate); Type 2 = islet amyloid (amylin/IAPP).
2. Kimmelstiel-Wilson nodule = nodular glomerulosclerosis = PAS-positive, Congo-red negative; most specific renal lesion of DM.
3. Diffuse GBM/mesangial thickening is the earliest and most universal renal change.
4. Hyaline arteriolosclerosis affects BOTH afferent and efferent arterioles in DM.
5. Armanni-Ebstein = glycogen vacuolation of renal tubular epithelium.
6. Microalbuminuria (30–300 mg/day) = earliest clinical sign of nephropathy + CV risk marker.
7. Polyol pathway (aldose reductase → sorbitol) → cataract & neuropathy in insulin-independent tissues.
8. Pericyte loss → microaneurysm = earliest retinopathy lesion; VEGF → neovascularisation = proliferative stage.
9. Diagnostic cut-offs: FPG ≥126, OGTT 2-h ≥200, HbA1c ≥6.5%, random ≥200 + symptoms.
10. C-peptide low in Type 1, normal/high in Type 2; anti-GAD65 + HLA-DR3/DR4 mark Type 1.
11. ACE-I/ARB renoprotective (efferent dilation); DM is the leading cause of ESRD and non-traumatic amputation.
12. DKA (T1, ketotic) vs HHS (T2, osmolality >320, minimal ketones); mucormycosis classically complicates DKA.